<code id='033E099E44'></code><style id='033E099E44'></style>
    • <acronym id='033E099E44'></acronym>
      <center id='033E099E44'><center id='033E099E44'><tfoot id='033E099E44'></tfoot></center><abbr id='033E099E44'><dir id='033E099E44'><tfoot id='033E099E44'></tfoot><noframes id='033E099E44'>

    • <optgroup id='033E099E44'><strike id='033E099E44'><sup id='033E099E44'></sup></strike><code id='033E099E44'></code></optgroup>
        1. <b id='033E099E44'><label id='033E099E44'><select id='033E099E44'><dt id='033E099E44'><span id='033E099E44'></span></dt></select></label></b><u id='033E099E44'></u>
          <i id='033E099E44'><strike id='033E099E44'><tt id='033E099E44'><pre id='033E099E44'></pre></tt></strike></i>

          Home / comprehensive / entertainment

          entertainment


          entertainment

          author:hotspot    Page View:991
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In